Literature DB >> 9858421

The classification of cyclooxygenase inhibitors.

L P Lipsky, S B Abramson, L Crofford, R N Dubois, L S Simon, L B van de Putte.   

Abstract

In summary, precise classification of COX inhibitors has important clinical implications for efficacy and toxicity. However, classification of these agents clinically is difficult because there are insufficient data to predict correlations between biochemical and pharmacologic properties and the clinical effect of a given agent. In any case, specific COX-2 inhibitors are expected to show antiinflammatory and analgesic activities equivalent to those of NSAID, as well as significant reductions in the incidence of the life threatening side effects (i.e., GI bleeding) associated with COX-1 inhibition. The advantages of preferential COX-2 inhibitors may be more subtle and therefore more difficult to verify in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858421

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

Review 1.  The genetics and neuropathology of Alzheimer's disease.

Authors:  Gerard D Schellenberg; Thomas J Montine
Journal:  Acta Neuropathol       Date:  2012-05-23       Impact factor: 17.088

2.  Management of Inflammatory Pain with Selective COX-2 Inhibitors: Promises and Facts.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

Review 3.  The second generation of COX-2 inhibitors: what advantages do the newest offer?

Authors:  Dirk O Stichtenoth; Jürgen C Frölich
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.

Authors:  D Clemett; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

5.  [Pharmacology of cyclooxygenase 2 inhibition].

Authors:  Eckhard Beubler
Journal:  Wien Med Wochenschr       Date:  2003

6.  Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.

Authors:  Hubert Blain; Christelle Boileau; Françoise Lapicque; Emmanuelle Nédélec; Damien Loeuille; Cécile Guillaume; Alain Gaucher; Claude Jeandel; Patrick Netter; Jean-Yves Jouzeau
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

Review 7.  Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis.

Authors:  Helmut Schmidt; Barry G Woodcock; Gerd Geisslinger
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  3-D structural interactions and quantitative structural toxicity studies of tyrosine derivatives intended for safe potent inflammation treatment.

Authors:  Ayarivan Puratchikody; Dharmaraj Sriram; Appavoo Umamaheswari; Navabshan Irfan
Journal:  Chem Cent J       Date:  2016-04-30       Impact factor: 4.215

9.  Absorption and distribution of etoricoxib in plasma, CSF, and wound tissue in patients following hip surgery--a pilot study.

Authors:  Bertold Renner; Josef Zacher; Asokumar Buvanendran; Gerrit Walter; Jochen Strauss; Kay Brune
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-06       Impact factor: 3.000

10.  COX-2 structural analysis and docking studies with gallic acid structural analogues.

Authors:  M Amaravani; Nirmal K Prasad; Vadde Ramakrishna
Journal:  Springerplus       Date:  2012-12-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.